FarFaR - Pharmacy Repository
University of Belgrade, Faculty of Pharmacy
    • English
    • Српски
    • Српски (Serbia)
  • English 
    • English
    • Serbian (Cyrillic)
    • Serbian (Latin)
  • Login
View Item 
  •   FarFaR
  • Pharmacy
  • Radovi istraživača / Researchers’ publications
  • View Item
  •   FarFaR
  • Pharmacy
  • Radovi istraživača / Researchers’ publications
  • View Item
JavaScript is disabled for your browser. Some features of this site may not work without it.

Adjuvants in vaccines registered for human use

Adjuvansi u vakcinama registrovanim za primenu kod ljudi

Thumbnail
2019
bitstream_7644.pdf (358.5Kb)
Authors
Filipić, Brankica
Stojić-Vukanić, Zorica
Article (Published version)
Metadata
Show full item record
Abstract
Vaccination is one of the most efficient strategies for prevention of infection diseases, but with introduction of sub-unit vaccines with lower immunogenicity adjuvants were needed to enhance the immune response. The term adjuvant is from Latin verb adjuvare which means „to aid”. Adjuvants have been used in vaccines for more than 90 years. The longest adjuvant history belongs to aluminium salts, but novel adjuvants have been introduced in licensed vaccines in last 30 years. These novel adjuvants are AS04, which consists of aluminium hydroxide and Toll-like receptor 4 (TLR4) agonist monophosphoryl lipid A and is used in hepatitis B vaccine Fendrix® and HPV vaccine Cervarix®, emulsion based adjuvants which are part of several influenza vaccines-MF59 (Fluad® and Focetria®) and AS03 (Pandemrix®), AS01 liposomal adjuvant which is combination of two distinct immunostimulatory molecules and is component of herpes zoster and malaria vaccine and virosomes included in hepatits A vaccine (Epaxal®...) and influenza vaccines (Inflexal® V and Invivac®). Adjuvant development and better insight into their mechanism of action are of great importance in order to replace empirical with rational use of adjuvants, without affecting vaccine safety.

Vakcinacija je jedna od najznačajnijih strategija za prevenciju infektivnih oboljenja, a razvoj subjediničnih vakcina doveo je do potrebe za primenom adjuvanasa u vakcinama. Naziv adjuvans potiče od latinske reči adjuvare što znači "pomoći". Adjuvansi su supstance koje se primenjuju u vakcinama više od 90 godina, a dodaju se da bi se povećala imunogenost antigena koji imaju nizak imunostimulatorni potencijal. U vakcinama za primenu kod ljudi, najduže se kao adjuvansi koriste soli aluminijuma, ali je poslednjih decenija nekoliko novih adjuvanasa uključeno u vakcine koje su odobrene za primenu. Adjuvantni sistem AS04, ulazi u sastav vakcina protiv humanog papiloma virusa (Cervarix®) i hepatitis B virusa (Fendrix®) i sadrži aluminijum hidroksid i TLR4 agonist, monofosforil lipid A. Zatim, adjuvansi na bazi emulzije (MF59 i AS03) su sastavni deo vakcina protiv gripa (Fluad®, Focetria® i Pandemrix®). Kombinacija dva imunostimulatorna molekula, označena kao AS01, ulazi u sastav vakcine proti...v herpes zoster virusa i malarije dok se adjuvansi na bazi virozoma koriste u vakcinama protiv hepatitisa A (Epaxal®) i gripa (Inflexal® V, Invivac®). Daljim razvojem adjuvanasa, i ispitivanjem njihovog mehanizma delovanja oni će se umesto empirijski, sve više koristili racionalno i ciljano, čime će se postići bolji imunogeni profil vakcina, bez narušavanja njihovog bezbednosnog profila.

Keywords:
Adjuvants / Immunogenicity / Vaccines / adjuvansi / vakcine / imunogenost
Source:
Arhiv za farmaciju, 2019, 69, 6, 406-419
Publisher:
  • Beograd : Savez farmaceutskih udruženja Srbije

DOI: 10.5937/arhfarm1906406F

ISSN: 0004-1963

Scopus: 2-s2.0-85080946644
[ Google Scholar ]
URI
https://farfar.pharmacy.bg.ac.rs/handle/123456789/3565
Collections
  • Radovi istraživača / Researchers’ publications
Institution/Community
Pharmacy
TY  - JOUR
AU  - Filipić, Brankica
AU  - Stojić-Vukanić, Zorica
PY  - 2019
UR  - https://farfar.pharmacy.bg.ac.rs/handle/123456789/3565
AB  - Vaccination is one of the most efficient strategies for prevention of infection diseases, but with introduction of sub-unit vaccines with lower immunogenicity adjuvants were needed to enhance the immune response. The term adjuvant is from Latin verb adjuvare which means „to aid”. Adjuvants have been used in vaccines for more than 90 years. The longest adjuvant history belongs to aluminium salts, but novel adjuvants have been introduced in licensed vaccines in last 30 years. These novel adjuvants are AS04, which consists of aluminium hydroxide and Toll-like receptor 4 (TLR4) agonist monophosphoryl lipid A and is used in hepatitis B vaccine Fendrix® and HPV vaccine Cervarix®, emulsion based adjuvants which are part of several influenza vaccines-MF59 (Fluad® and Focetria®) and AS03 (Pandemrix®), AS01 liposomal adjuvant which is combination of two distinct immunostimulatory molecules and is component of herpes zoster and malaria vaccine and virosomes included in hepatits A vaccine (Epaxal®) and influenza vaccines (Inflexal® V and Invivac®). Adjuvant development and better insight into their mechanism of action are of great importance in order to replace empirical with rational use of adjuvants, without affecting vaccine safety.
AB  - Vakcinacija je jedna od najznačajnijih strategija za prevenciju infektivnih oboljenja, a razvoj subjediničnih vakcina doveo je do potrebe za primenom adjuvanasa u vakcinama. Naziv adjuvans potiče od latinske reči adjuvare što znači "pomoći". Adjuvansi su supstance koje se primenjuju u vakcinama više od 90 godina, a dodaju se da bi se povećala imunogenost antigena koji imaju nizak imunostimulatorni potencijal. U vakcinama za primenu kod ljudi, najduže se kao adjuvansi koriste soli aluminijuma, ali je poslednjih decenija nekoliko novih adjuvanasa uključeno u vakcine koje su odobrene za primenu. Adjuvantni sistem AS04, ulazi u sastav vakcina protiv humanog papiloma virusa (Cervarix®) i hepatitis B virusa (Fendrix®) i sadrži aluminijum hidroksid i TLR4 agonist, monofosforil lipid A. Zatim, adjuvansi na bazi emulzije (MF59 i AS03) su sastavni deo vakcina protiv gripa (Fluad®, Focetria® i Pandemrix®). Kombinacija dva imunostimulatorna molekula, označena kao AS01, ulazi u sastav vakcine protiv herpes zoster virusa i malarije dok se adjuvansi na bazi virozoma koriste u vakcinama protiv hepatitisa A (Epaxal®) i gripa (Inflexal® V, Invivac®). Daljim razvojem adjuvanasa, i ispitivanjem njihovog mehanizma delovanja oni će se umesto empirijski, sve više koristili racionalno i ciljano, čime će se postići bolji imunogeni profil vakcina, bez narušavanja njihovog bezbednosnog profila.
PB  - Beograd : Savez farmaceutskih udruženja Srbije
T2  - Arhiv za farmaciju
T1  - Adjuvants in vaccines registered for human use
T1  - Adjuvansi u vakcinama registrovanim    za primenu kod ljudi
VL  - 69
IS  - 6
SP  - 406
EP  - 419
DO  - 10.5937/arhfarm1906406F
ER  - 
@article{
author = "Filipić, Brankica and Stojić-Vukanić, Zorica",
year = "2019",
abstract = "Vaccination is one of the most efficient strategies for prevention of infection diseases, but with introduction of sub-unit vaccines with lower immunogenicity adjuvants were needed to enhance the immune response. The term adjuvant is from Latin verb adjuvare which means „to aid”. Adjuvants have been used in vaccines for more than 90 years. The longest adjuvant history belongs to aluminium salts, but novel adjuvants have been introduced in licensed vaccines in last 30 years. These novel adjuvants are AS04, which consists of aluminium hydroxide and Toll-like receptor 4 (TLR4) agonist monophosphoryl lipid A and is used in hepatitis B vaccine Fendrix® and HPV vaccine Cervarix®, emulsion based adjuvants which are part of several influenza vaccines-MF59 (Fluad® and Focetria®) and AS03 (Pandemrix®), AS01 liposomal adjuvant which is combination of two distinct immunostimulatory molecules and is component of herpes zoster and malaria vaccine and virosomes included in hepatits A vaccine (Epaxal®) and influenza vaccines (Inflexal® V and Invivac®). Adjuvant development and better insight into their mechanism of action are of great importance in order to replace empirical with rational use of adjuvants, without affecting vaccine safety., Vakcinacija je jedna od najznačajnijih strategija za prevenciju infektivnih oboljenja, a razvoj subjediničnih vakcina doveo je do potrebe za primenom adjuvanasa u vakcinama. Naziv adjuvans potiče od latinske reči adjuvare što znači "pomoći". Adjuvansi su supstance koje se primenjuju u vakcinama više od 90 godina, a dodaju se da bi se povećala imunogenost antigena koji imaju nizak imunostimulatorni potencijal. U vakcinama za primenu kod ljudi, najduže se kao adjuvansi koriste soli aluminijuma, ali je poslednjih decenija nekoliko novih adjuvanasa uključeno u vakcine koje su odobrene za primenu. Adjuvantni sistem AS04, ulazi u sastav vakcina protiv humanog papiloma virusa (Cervarix®) i hepatitis B virusa (Fendrix®) i sadrži aluminijum hidroksid i TLR4 agonist, monofosforil lipid A. Zatim, adjuvansi na bazi emulzije (MF59 i AS03) su sastavni deo vakcina protiv gripa (Fluad®, Focetria® i Pandemrix®). Kombinacija dva imunostimulatorna molekula, označena kao AS01, ulazi u sastav vakcine protiv herpes zoster virusa i malarije dok se adjuvansi na bazi virozoma koriste u vakcinama protiv hepatitisa A (Epaxal®) i gripa (Inflexal® V, Invivac®). Daljim razvojem adjuvanasa, i ispitivanjem njihovog mehanizma delovanja oni će se umesto empirijski, sve više koristili racionalno i ciljano, čime će se postići bolji imunogeni profil vakcina, bez narušavanja njihovog bezbednosnog profila.",
publisher = "Beograd : Savez farmaceutskih udruženja Srbije",
journal = "Arhiv za farmaciju",
title = "Adjuvants in vaccines registered for human use, Adjuvansi u vakcinama registrovanim    za primenu kod ljudi",
volume = "69",
number = "6",
pages = "406-419",
doi = "10.5937/arhfarm1906406F"
}
Filipić, B.,& Stojić-Vukanić, Z.. (2019). Adjuvants in vaccines registered for human use. in Arhiv za farmaciju
Beograd : Savez farmaceutskih udruženja Srbije., 69(6), 406-419.
https://doi.org/10.5937/arhfarm1906406F
Filipić B, Stojić-Vukanić Z. Adjuvants in vaccines registered for human use. in Arhiv za farmaciju. 2019;69(6):406-419.
doi:10.5937/arhfarm1906406F .
Filipić, Brankica, Stojić-Vukanić, Zorica, "Adjuvants in vaccines registered for human use" in Arhiv za farmaciju, 69, no. 6 (2019):406-419,
https://doi.org/10.5937/arhfarm1906406F . .

DSpace software copyright © 2002-2015  DuraSpace
About FarFaR - Pharmacy Repository | Send Feedback

OpenAIRERCUB
 

 

All of DSpaceCommunitiesAuthorsTitlesSubjectsThis institutionAuthorsTitlesSubjects

Statistics

View Usage Statistics

DSpace software copyright © 2002-2015  DuraSpace
About FarFaR - Pharmacy Repository | Send Feedback

OpenAIRERCUB